Trial · NCT07833436
A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever
NCT07833436, Phase 1, Recruiting, Institut Pasteur
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever. Trials, record NCT07833436. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07833436
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever
- NCT number
- NCT07833436
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 72 participants, estimated
- Lead sponsor
- Institut Pasteur
- Conditions
- Lassa Fever
- Interventions
- Low dose MOPEVAC-Las vaccine, Intermediate dose MOPEVAC-Las vaccine, High dose MOPEVAC-Las vaccine, Saline Solution for Injection
- First posted
- 2026-09-22
- Last updated
- 2026-10-13
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of solicited and unsolicited Adverse Events (AEs) during the treatment period up to 28 days after each injection. | From each injection to 28 days later | |
| Secondary | Measurement of functional CD4+ and CD8+ T- cells to assess cell-mediated immunity specific for MOPEVAC-Las | On days 14 and 28 after each injection, and 6 months and 1 year after the second injection (i.e. day 242 and 425) | |
| Secondary | Measurement of anti-LASV antibodies determined by ELISA assay | The day of each injection and 7, 14 and 28 days after each injection | |
| Secondary | Quantification of functional, neutralizing antibodies via Virus Neutralization Test (VNT) | On days 0, 14, 28, 60, 74, 88, 242 and 425 | |
| Secondary | Rate of serious adverse events (SAEs), serious adverse reactions (SARs), suspected unexpected serious adverse reactions (SUSARs) and adverse events of special interest (AESI) | From the first injection until 1 year after the second injection |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07833436
GET https://conductscience.org/api/trials/v1/NCT07833436/registered